Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Capital Expenditures (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Capital Expenditures for 3 consecutive years, with -$21000.0 as the latest value for Q2 2025.

  • On a quarterly basis, Capital Expenditures rose 97.7% to -$21000.0 in Q2 2025 year-over-year; TTM through Sep 2025 was $16000.0, a 99.18% decrease, with the full-year FY2024 number at $2.6 million, up 400.39% from a year prior.
  • Capital Expenditures was -$21000.0 for Q2 2025 at Inhibrx Biosciences, down from $21000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $2.4 million in Q3 2024 to a low of -$912000.0 in Q2 2024.
  • A 3-year average of $347000.0 and a median of $18500.0 in 2024 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: soared 192.73% in 2024, then tumbled 98.12% in 2025.
  • Inhibrx Biosciences' Capital Expenditures stood at -$632000.0 in 2023, then soared by 102.53% to $16000.0 in 2024, then plummeted by 231.25% to -$21000.0 in 2025.
  • Per Business Quant, the three most recent readings for INBX's Capital Expenditures are -$21000.0 (Q2 2025), $21000.0 (Q1 2025), and $16000.0 (Q4 2024).